GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syros Pharmaceuticals Inc (NAS:SYRS) » Definitions » Market Cap

Syros Pharmaceuticals (Syros Pharmaceuticals) Market Cap : $149.41 Mil (As of May. 01, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Syros Pharmaceuticals Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Syros Pharmaceuticals's share price for the quarter that ended in Dec. 2023 was $7.79. Syros Pharmaceuticals's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 26.45 Mil. Therefore, Syros Pharmaceuticals's market cap for the quarter that ended in Dec. 2023 was $206.04 Mil.

Syros Pharmaceuticals's quarterly market cap increased from Jun. 2023 ($65.23 Mil) to Sep. 2023 ($81.85 Mil) and increased from Sep. 2023 ($81.85 Mil) to Dec. 2023 ($206.04 Mil).

Syros Pharmaceuticals's annual market cap declined from Dec. 2021 ($202.20 Mil) to Dec. 2022 ($72.74 Mil) but then increased from Dec. 2022 ($72.74 Mil) to Dec. 2023 ($206.04 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Syros Pharmaceuticals's Enterprise Value for Today is $66.08 Mil.


Syros Pharmaceuticals Market Cap Historical Data

The historical data trend for Syros Pharmaceuticals's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syros Pharmaceuticals Market Cap Chart

Syros Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 299.67 610.02 202.20 72.74 206.04

Syros Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 72.74 54.49 65.23 81.85 206.04

Competitive Comparison of Syros Pharmaceuticals's Market Cap

For the Biotechnology subindustry, Syros Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syros Pharmaceuticals's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Syros Pharmaceuticals's Market Cap distribution charts can be found below:

* The bar in red indicates where Syros Pharmaceuticals's Market Cap falls into.



Syros Pharmaceuticals Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Syros Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=$7.79*26.4487
=$206.04

Syros Pharmaceuticals's Market Cap for the quarter that ended in Dec. 2023 is calculated as

Market Cap (Q: Dec. 2023 )=Share Price (Q: Dec. 2023 )*Shares Outstanding (EOP) (Q: Dec. 2023 )
=$7.79*26.4487
=$206.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Syros Pharmaceuticals  (NAS:SYRS) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Syros Pharmaceuticals Market Cap Related Terms

Thank you for viewing the detailed overview of Syros Pharmaceuticals's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Syros Pharmaceuticals (Syros Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
35 CambridgePark Drive, 4th Floor, Cambridge, MA, USA, 02140
Syros Pharmaceuticals Inc is a biopharmaceutical company engaged in a non-coding regulatory region of the genome controlling the activation and repression of genes. It is mainly involved in the segments of pharmaceutical, biotechnology, and other related markets that address gene control and cancer. The Company operates only in the United States.
Executives
Srinivas Akkaraju director 565 EVERETT AVENUE, PALO ALTO CA 94301
David Roth officer: Chief Medical Officer C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Eric R Olson officer: Chief Scientific Officer C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE, SUITE 300, CAMBRIDGE MA 02139
Timothy Tyson director ONE ENTERPRISE, ALISO VIEJO CA 92656
Andrew M. Oh director C/O RUBIUS THERAPEUTICS, 325 VASSAR ST., STE. 1A, CAMBRIDGE MA 02139
Jason Haas officer: Chief Financial Officer C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Chee Conley officer: Chief Commercial Officer C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Deborah Dunsire director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Kristin Stephens officer: Chief Development Officer C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Richard A Young director C/O SYROS PHARMACEUTICALS, INC., 620 MEMORIAL DRIVE SUITE 300, CAMBRIDGE MA 02139
Sue Gail Eckhardt director C/O SYROS PHARMACEUTICALS, INC., 35 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Mark J Alles director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Jeremy P. Springhorn officer: Chief Business Officer C/O UNIQUIRE N.V., 113 HARTWELL AVENUE, LEXINGTON MA 02421
Arch Venture Fund Vii, L.p. 10 percent owner 8755 W HIGGINS, SUITE 1025, Chicago IL 60631
Alice Tsang Shaw director MASSACHUSETTS GENERAL HOSPITAL, 55 FRUIT ST., #148, BOSTON MA 02114